Senti Biosciences, Inc. (NASDAQ:SNTI) Short Interest Update

Senti Biosciences, Inc. (NASDAQ:SNTI) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totaling 792,811 shares, a decline of 22.3% from the December 31st total of 1,019,881 shares. Based on an average daily trading volume, of 265,433 shares, the short-interest ratio is presently 3.0 days. Approximately 3.1% of the company’s shares are short sold. Approximately 3.1% of the company’s shares are short sold. Based on an average daily trading volume, of 265,433 shares, the short-interest ratio is presently 3.0 days.

Senti Biosciences Price Performance

NASDAQ SNTI traded down $0.02 on Friday, reaching $1.00. The company’s stock had a trading volume of 195,519 shares, compared to its average volume of 269,171. Senti Biosciences has a twelve month low of $1.00 and a twelve month high of $5.10. The firm’s 50 day moving average is $1.36 and its two-hundred day moving average is $1.58.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.10). As a group, analysts expect that Senti Biosciences will post -14.54 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on SNTI. HC Wainwright assumed coverage on Senti Biosciences in a report on Tuesday, October 14th. They issued a “buy” rating and a $12.00 price objective for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Leerink Partners started coverage on shares of Senti Biosciences in a research report on Friday, November 21st. They set an “outperform” rating and a $6.00 target price on the stock. Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a research note on Saturday, December 13th. Finally, Chardan Capital increased their price objective on shares of Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Senti Biosciences currently has an average rating of “Moderate Buy” and an average price target of $9.00.

Institutional Trading of Senti Biosciences

Hedge funds have recently made changes to their positions in the company. Geode Capital Management LLC lifted its holdings in Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the period. Armistice Capital LLC acquired a new stake in Senti Biosciences during the second quarter valued at approximately $1,883,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Senti Biosciences during the third quarter worth $117,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.